271 related articles for article (PubMed ID: 37035317)
1. Effectiveness of mid-regional pro-adrenomedullin, compared to other biomarkers (including lymphocyte subpopulations and immunoglobulins), as a prognostic biomarker in COVID-19 critically ill patients: New evidence from a 15-month observational prospective study.
Montrucchio G; Sales G; Balzani E; Lombardo D; Giaccone A; Cantù G; D'Antonio G; Rumbolo F; Corcione S; Simonetti U; Bonetto C; Zanierato M; Fanelli V; Filippini C; Mengozzi G; Brazzi L
Front Med (Lausanne); 2023; 10():1122367. PubMed ID: 37035317
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: An observational prospective study.
Montrucchio G; Sales G; Rumbolo F; Palmesino F; Fanelli V; Urbino R; Filippini C; Mengozzi G; Brazzi L
PLoS One; 2021; 16(2):e0246771. PubMed ID: 33556140
[TBL] [Abstract][Full Text] [Related]
3. Mid-regional pro-adrenomedullin predicts poor outcome in non-selected patients admitted to an intensive care unit.
Bellia C; Agnello L; Lo Sasso B; Bivona G; Raineri MS; Giarratano A; Ciaccio M
Clin Chem Lab Med; 2019 Mar; 57(4):549-555. PubMed ID: 30157027
[TBL] [Abstract][Full Text] [Related]
4. High levels of mid-regional proadrenomedullin in ARDS COVID-19 patients: the experience of a single, Italian Center.
Benedetti I; Spinelli D; Callegari T; Bonometti R; Molinaro E; Novara E; Cassinari M; Frino C; Guaschino R; Boverio R; Lauritano EC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1743-1751. PubMed ID: 33629344
[TBL] [Abstract][Full Text] [Related]
5. Does mid-regional pro-adrenomedullin (MR-proADM) improve the sequential organ failure assessment-score (SOFA score) for mortality-prediction in patients with acute infections? Results of a prospective observational study.
Haag E; Gregoriano C; Molitor A; Kloter M; Kutz A; Mueller B; Schuetz P
Clin Chem Lab Med; 2021 May; 59(6):1165-1176. PubMed ID: 33554514
[TBL] [Abstract][Full Text] [Related]
6. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study.
Christ-Crain M; Morgenthaler NG; Struck J; Harbarth S; Bergmann A; Müller B
Crit Care; 2005; 9(6):R816-24. PubMed ID: 16356231
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis.
Bernal-Morell E; García-Villalba E; Vera MDC; Medina B; Martinez M; Callejo V; Valero S; Cinesi C; Piñera P; Alcaraz A; Marin I; Muñoz A; Cano A
J Infect; 2018 Mar; 76(3):249-257. PubMed ID: 29246637
[TBL] [Abstract][Full Text] [Related]
8. Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?
Pereira JM; Azevedo A; Basílio C; Sousa-Dias C; Mergulhão P; Paiva JA
Rev Port Pneumol (2006); 2016; 22(6):308-314. PubMed ID: 27160747
[TBL] [Abstract][Full Text] [Related]
9. Endothelium-associated biomarkers mid-regional proadrenomedullin and C-terminal proendothelin-1 have good ability to predict 28-day mortality in critically ill patients with SARS-CoV-2 pneumonia: A prospective cohort study.
van Oers JAH; Kluiters Y; Bons JAP; de Jongh M; Pouwels S; Ramnarain D; de Lange DW; de Grooth HJ; Girbes ARJ
J Crit Care; 2021 Dec; 66():173-180. PubMed ID: 34340901
[TBL] [Abstract][Full Text] [Related]
10. Superior accuracy of mid-regional proadrenomedullin for mortality prediction in sepsis with varying levels of illness severity.
Andaluz-Ojeda D; Nguyen HB; Meunier-Beillard N; Cicuéndez R; Quenot JP; Calvo D; Dargent A; Zarca E; Andrés C; Nogales L; Eiros JM; Tamayo E; Gandía F; Bermejo-Martín JF; Charles PE
Ann Intensive Care; 2017 Dec; 7(1):15. PubMed ID: 28185230
[TBL] [Abstract][Full Text] [Related]
11. Mid-Regional Pro-Adrenomedullin as a Prognostic Factor for Severe COVID-19 ARDS.
de Montmollin E; Peoc'h K; Marzouk M; Ruckly S; Wicky PH; Patrier J; Jaquet P; Sonneville R; Bouadma L; Timsit JF
Antibiotics (Basel); 2022 Aug; 11(9):. PubMed ID: 36139946
[TBL] [Abstract][Full Text] [Related]
12. The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: an observational study.
Gregoriano C; Koch D; Kutz A; Haubitz S; Conen A; Bernasconi L; Hammerer-Lercher A; Saeed K; Mueller B; Schuetz P
Clin Chem Lab Med; 2021 Apr; 59(5):995-1004. PubMed ID: 33554516
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission.
Gonzalez Del Castillo J; Wilson DC; Clemente-Callejo C; Román F; Bardés-Robles I; Jiménez I; Orviz E; Dastis-Arias M; Espinosa B; Tornero-Romero F; Giol-Amich J; González V; Llopis-Roca F;
Crit Care; 2019 Oct; 23(1):335. PubMed ID: 31665092
[TBL] [Abstract][Full Text] [Related]
14. Mid-Regional Proadrenomedullin and Mid-Regional Proatrial Natriuretic Peptide Clearance Predicts Poor Outcomes Better Than Single Baseline Measurements in Critically Ill Patients With Pneumonia: A Retrospective Cohort Study.
Van Oers J; Krabbe J; Kemna E; Kluiters Y; Vos P; De Lange D; Girbes A; Beishuizen A
Cureus; 2021 May; 13(5):e15285. PubMed ID: 34221750
[TBL] [Abstract][Full Text] [Related]
15. Plasma levels of mid-regional pro-adrenomedullin in sepsis are associated with risk of death.
Valenzuela-Sánchez F; Valenzuela-Méndez B; Bohollo de Austria R; Rodríguez-Gutiérrez JF; Estella-García Á; Fernández-Ruiz L; González-García MÁ; Rello J
Minerva Anestesiol; 2019 Apr; 85(4):366-375. PubMed ID: 30207133
[TBL] [Abstract][Full Text] [Related]
16. Identification of COVID-19 patients at risk of hospital admission and mortality: a European multicentre retrospective analysis of mid-regional pro-adrenomedullin.
Sozio E; Moore NA; Fabris M; Ripoli A; Rumbolo F; Minieri M; Boverio R; Rodríguez Mulero MD; Lainez-Martinez S; Martínez Martínez M; Calvo D; Gregoriano C; Williams R; Brazzi L; Terrinoni A; Callegari T; Hernández Olivo M; Esteban-Torrella P; Calcerrada I; Bernasconi L; Kidd SP; Sbrana F; Miguens I; Gordon K; Visentini D; Legramante JM; Bassi F; Cortes N; Montrucchio G; Di Lecce VN; Lauritano EC; García de Guadiana-Romualdo L; González Del Castillo J; Bernal-Morell E; Andaluz-Ojeda D; Schuetz P; Curcio F; Tascini C; Saeed K
Respir Res; 2022 Aug; 23(1):221. PubMed ID: 36031619
[TBL] [Abstract][Full Text] [Related]
17. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.
Travaglino F; Russo V; De Berardinis B; Numeroso F; Catania P; Cervellin G; Nigra SG; Geraci F; Bressan MA; Guerrini S; Cavazza M; Folli C; Monzani V; Battista S; Mengozzi G; Noto P; Carpinteri G; Semplicini A; Stella F; Ingrassia S; Moscatelli P; Giuntini P; Salerno G; Cardelli P; Di Somma S
Am J Emerg Med; 2014 Apr; 32(4):334-41. PubMed ID: 24559907
[TBL] [Abstract][Full Text] [Related]
18. Mid-regional pro-adrenomedullin and lactate levels for risk stratification in patients with out-of-hospital cardiac arrest.
Zelniker TA; Schwall D; Hamidi F; Steinbach S; Scheller P; Spaich S; Michels G; Giannitsis E; Katus HA; Frey N; Preusch MR
Eur Heart J Acute Cardiovasc Care; 2023 Jun; 12(6):364-371. PubMed ID: 36943296
[TBL] [Abstract][Full Text] [Related]
19. Mid-Regional Pro-Adrenomedullin, Methemoglobin and Carboxyhemoglobin as Prognosis Biomarkers in Critically Ill Patients with COVID-19: An Observational Prospective Study.
Oblitas CM; Galeano-Valle F; Ramírez-Navarro J; López-Cano J; Monterrubio-Manrique Á; García-Gámiz M; Sancho-González M; Arenal-López S; Álvarez-Sala Walther LA; Demelo-Rodríguez P
Viruses; 2021 Dec; 13(12):. PubMed ID: 34960714
[TBL] [Abstract][Full Text] [Related]
20. Mid-regional pro-adrenomedullin as a predictor of in-hospital mortality in adult patients with COVID-19: a single-centre prospective study.
Popov D; Borovkova U; Rybka M; Ramnyonok T; Golukhova E
Anaesthesiol Intensive Ther; 2022; 54(3):242-246. PubMed ID: 36062419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
